Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLDNASDAQ:ARMNASDAQ:CRWVNASDAQ:NBISNASDAQ:NVDANASDAQ:RXRXNASDAQ:WRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLDApplied Digital$7.48+10.3%$5.55$3.01▼$12.48$1.68B5.9830.70 million shs55.76 million shsARMARM$129.28-0.9%$112.62$80.00▼$188.75$135.46B4.396.97 million shs2.36 million shsCRWVCoreWeave, Inc. Class A Common Stock$100.16-6.7%$52.92$33.51▼$116.54$46.48BN/A17.58 million shs60.79 million shsNBISNebius Group$37.80-2.9%$26.02$14.09▼$50.87$8.91B3.1110.54 million shs10.88 million shsNVDANVIDIA$132.83+0.8%$113.31$86.62▼$195.95$3.25T2.11292.03 million shs186.69 million shsRXRXRecursion Pharmaceuticals$4.14+1.2%$5.18$3.79▼$12.36$1.68B0.9913.35 million shs16.58 million shsWRDWeRide$10.08-1.8%$10.54$6.03▼$44.00$2.68BN/A6.32 million shs25.09 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLDApplied Digital+0.74%+13.38%+71.65%-33.40%+53.39%ARMARM-0.45%-2.25%+34.72%-13.52%+13.66%CRWVCoreWeave, Inc. Class A Common Stock+19.00%+59.19%+203.19%+10,738,999,900.00%+10,738,999,900.00%NBISNebius Group-0.56%+7.75%+87.84%-15.85%+3,891,999,900.00%NVDANVIDIA-1.92%-2.62%+36.00%-5.93%+38.18%RXRXRecursion Pharmaceuticals-10.11%-5.10%-24.40%-60.48%-56.99%WRDWeRide+21.42%+8.69%+21.56%-62.81%+1,025,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLDApplied Digital3.8018 of 5 stars4.53.00.00.04.02.50.6ARMARM3.1152 of 5 stars3.35.00.00.02.50.01.9CRWVCoreWeave, Inc. Class A Common StockN/AN/AN/AN/AN/AN/AN/AN/ANBISNebius Group1.9334 of 5 stars3.60.00.00.03.10.00.6NVDANVIDIA4.7844 of 5 stars3.45.01.73.02.82.51.9RXRXRecursion Pharmaceuticals2.4179 of 5 stars3.23.00.00.02.42.50.6WRDWeRideN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLDApplied Digital 3.00Buy$10.9145.84% UpsideARMARM 2.68Moderate Buy$152.7618.16% UpsideCRWVCoreWeave, Inc. Class A Common Stock 2.40Hold$58.44-41.66% DownsideNBISNebius Group 3.25Buy$50.6734.04% UpsideNVDANVIDIA 2.89Moderate Buy$164.8424.10% UpsideRXRXRecursion Pharmaceuticals 2.33Hold$7.6083.57% UpsideWRDWeRide 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NVDA, CRWV, ARM, APLD, NBIS, WRD, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025APLDApplied DigitalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$12.005/22/2025APLDApplied DigitalCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.005/22/2025CRWVCoreWeave, Inc. Class A Common StockJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform5/22/2025CRWVCoreWeave, Inc. Class A Common StockCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform5/22/2025NVDANVIDIAWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$175.005/21/2025CRWVCoreWeave, Inc. Class A Common StockCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$43.00 ➝ $94.005/21/2025NBISNebius GroupNorthland SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$34.00 ➝ $47.005/21/2025NBISNebius GroupBWS FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/19/2025NBISNebius GroupDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $45.005/16/2025CRWVCoreWeave, Inc. Class A Common StockThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$54.00 ➝ $61.005/16/2025CRWVCoreWeave, Inc. Class A Common StockJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$43.00 ➝ $66.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLDApplied Digital$221.19M7.60N/AN/A$0.91 per share8.22ARMARM$4.01B33.81$0.47 per share276.60$5.15 per share25.10CRWVCoreWeave, Inc. Class A Common Stock$2.71B17.16N/AN/AN/A∞NBISNebius Group$117.50M75.84$1.97 per share19.16$9.14 per share4.14NVDANVIDIA$130.50B24.89$1.18 per share112.93$1.72 per share77.23RXRXRecursion Pharmaceuticals$59.82M28.13N/AN/A$1.98 per share2.09WRDWeRide$361.13M7.43N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLDApplied Digital-$149.27M-$1.37N/AN/AN/A-127.86%-117.67%-27.84%N/AARMARM$306M$0.75170.11111.456.3321.82%11.94%8.62%7/30/2025 (Estimated)CRWVCoreWeave, Inc. Class A Common StockN/AN/A0.00∞N/AN/AN/AN/AN/ANBISNebius Group$221.50M-$0.57N/AN/AN/A-4.76%7.18%4.00%7/28/2025 (Estimated)NVDANVIDIA$29.76B$2.9452.2733.371.7655.69%114.83%76.61%5/28/2025 (Estimated)RXRXRecursion Pharmaceuticals-$328.07M-$1.77N/AN/AN/A-579.52%-76.56%-55.68%N/AWRDWeRide-$275.41MN/A0.00N/AN/AN/AN/AN/AN/ALatest NVDA, CRWV, ARM, APLD, NBIS, WRD, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2025Q1 2026NVDANVIDIA$0.87N/AN/AN/A$43.09 billionN/A5/21/2025Q1 2025WRDWeRideN/A-$0.18N/A-$0.18N/A$9.98 million5/14/2025Q1 2025CRWVCoreWeave, Inc. Class A Common Stock-$0.16-$0.83-$0.67-$1.49N/AN/A5/7/2025Q4 2025ARMARM$0.52$0.55+$0.03$0.20$1.23 billion$1.24 billion5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million4/14/2025Q3 2025APLDApplied Digital-$0.11-$0.16-$0.05-$0.16$62.91 million$52.92 million3/14/2025Q4 2024WRDWeRideN/A-$0.29N/A-$0.33N/A$19.29 million2/28/2025Q4 2024RXRXRecursion Pharmaceuticals-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 million2/26/2025Q4 2025NVDANVIDIA$0.84$0.89+$0.05$0.89$38.16 billion$39.33 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLDApplied DigitalN/AN/AN/AN/AN/AARMARMN/AN/AN/AN/AN/ACRWVCoreWeave, Inc. Class A Common StockN/AN/AN/AN/AN/ANBISNebius GroupN/AN/AN/AN/AN/ANVDANVIDIA$0.040.03%+33.42%1.36%1 YearsRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/AWRDWeRideN/AN/AN/AN/AN/ALatest NVDA, CRWV, ARM, APLD, NBIS, WRD, and RXRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/26/2025NVDANVIDIAquarterly$0.010.03%3/12/20253/12/20254/2/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLDApplied Digital1.220.770.77ARMARMN/A4.964.96CRWVCoreWeave, Inc. Class A Common StockN/AN/AN/ANBISNebius GroupN/A22.2422.24NVDANVIDIA0.134.103.64RXRXRecursion Pharmaceuticals0.044.354.35WRDWeRideN/A0.480.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLDApplied Digital65.67%ARMARM7.53%CRWVCoreWeave, Inc. Class A Common StockN/ANBISNebius Group21.90%NVDANVIDIA65.27%RXRXRecursion Pharmaceuticals89.06%WRDWeRideN/AInsider OwnershipCompanyInsider OwnershipAPLDApplied Digital11.81%ARMARMN/ACRWVCoreWeave, Inc. Class A Common StockN/ANBISNebius GroupN/ANVDANVIDIA4.23%RXRXRecursion Pharmaceuticals15.75%WRDWeRide2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLDApplied Digital121224.72 million196.58 millionOptionableARMARM7,0961.05 billionN/ANot OptionableCRWVCoreWeave, Inc. Class A Common Stock881464.10 millionN/AN/ANBISNebius Group26,361235.75 millionN/AN/ANVDANVIDIA26,20024.46 billion23.45 billionOptionableRXRXRecursion Pharmaceuticals400406.50 million329.18 millionOptionableWRDWeRide2,227266.26 million250.19 millionN/ANVDA, CRWV, ARM, APLD, NBIS, WRD, and RXRX HeadlinesRecent News About These CompaniesThese Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio (WRD)May 22 at 11:57 AM | marketbeat.comWill Tencent Give WeRide the Edge in the Robotaxi Race?May 22 at 10:15 AM | zacks.comWeRide Inc. (NASDAQ:WRD) Q1 2025 Earnings Call TranscriptMay 22 at 9:12 AM | insidermonkey.comWeRide Narrows Losses In Q1, Announces $100M Share Repurchase Program: Retail’s ThrilledMay 21 at 7:11 PM | msn.comWhy WeRide board see WRD shares as undervaluedMay 21 at 7:11 PM | invezz.comWhat's Going On With WeRide Stock On Wednesday?May 21 at 7:11 PM | finance.yahoo.comWhy WeRide Stock Soared TodayMay 21 at 6:03 PM | fool.comWeRide Inc. (WRD) Q1 2025 Earnings Call TranscriptMay 21 at 2:04 PM | seekingalpha.comWeRide Announces Plan to Expand Commercial Robotaxi Services to 15 Additional Cities GloballyMay 21 at 5:10 AM | globenewswire.comWeRide Inc. Announces US$100 Million Share Repurchase ProgramMay 21 at 5:10 AM | globenewswire.comWeRide Inc.: WeRide and Tencent Cloud Expand Strategic Partnership to Drive Robotaxi CommercializationMay 20 at 1:31 PM | finanznachrichten.deWeRide Teams Up With Tencent Cloud To Accelerate Global Robotaxi AmbitionsMay 20 at 1:31 PM | msn.comWeRide and Tencent expand their robotaxi partnershipMay 20 at 1:31 PM | msn.comWeRide and Tencent Cloud Expand Strategic Partnership to Drive Robotaxi CommercializationMay 20 at 11:40 AM | globenewswire.comWeRide joins Tencent Cloud to build smart driving services for overseas marketsMay 20 at 6:58 AM | reuters.comAll You Need to Know About WeRide Inc. (WRD) Rating Upgrade to BuyMay 19 at 1:01 PM | zacks.comWeRide Launches Fully Driverless Robotaxi Trial Operations In Abu DhabiMay 18, 2025 | nasdaq.comWeRide Launches Robotaxi Trial Operations In Abu DhabiMay 16, 2025 | benzinga.comWeRide launches robotaxi operations in Abu Dhabi in high-demand areasMay 16, 2025 | msn.comWeRide Inc.’s Strategic Expansion and Growth Potential Earns Buy RatingMay 16, 2025 | tipranks.comWeRide Launches Fully Driverless Robotaxi Trial Operations in Abu Dhabi, Broadens Service CoverageMay 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreBy Sam Quirke | May 14, 2025View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreIntel Makes a Cool Move With Shell, But Will Investors Warm Up?By Jeffrey Neal Johnson | May 15, 2025View Intel Makes a Cool Move With Shell, But Will Investors Warm Up?The 5 Top Buys for May: Strong Signals at Critical Support LevelsBy Thomas Hughes | April 30, 2025View The 5 Top Buys for May: Strong Signals at Critical Support LevelsThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioNVDA, CRWV, ARM, APLD, NBIS, WRD, and RXRX Company DescriptionsApplied Digital NASDAQ:APLD$7.48 +0.70 (+10.32%) As of 04:00 PM EasternApplied Digital Corporation designs, develops, and operates datacenters in North America. Its datacenters provide digital infrastructure solutions to the high-performance computing industry. The company also provides artificial intelligence cloud services, high performance computing datacenter hosting, and crypto datacenter hosting services. The company was formerly known as Applied Blockchain, Inc. and changed its name to Applied Digital Corporation in November 2022. Applied Digital Corporation is based in Dallas, Texas.ARM NASDAQ:ARM$129.28 -1.17 (-0.90%) Closing price 04:00 PM EasternExtended Trading$129.47 +0.19 (+0.15%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.CoreWeave, Inc. Class A Common Stock NASDAQ:CRWV$100.16 -7.23 (-6.73%) As of 04:00 PM EasternCoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.Nebius Group NASDAQ:NBIS$37.80 -1.12 (-2.88%) Closing price 04:00 PM EasternExtended Trading$37.78 -0.02 (-0.05%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nebius Group N.V., a technology company, builds intelligent products and services powered by machine learning and other technologies to help consumers and businesses navigate the online and offline world. The company's services include Nebius AI, an AI-centric cloud platform that offers infrastructure and computing capability for AI deployment and machine-learning oriented solutions; and Toloka AI that offers generative AI (GenAI) solutions at every stage of the GenAI lifecycle, such as data annotation and generation, model training and fine-tuning, and quality assessment of large language model for accuracy and reliability. It also offers Avride, an autonomous driving solution which targets ride-hailing, logistics, e-commerce, and food/grocery delivery as application domains, as well as focuses on autonomous vehicles and delivery robots; and TripleTen, an EdTech service that prepares specialists for STEM roles, and equipping them with essential technology skills. The company was formerly known as Yandex N.V. and changed its name to Nebius Group N.V. in August 2024. Nebius Group N.V. was founded in 1989 and is based in Schiphol, the Netherlands.NVIDIA NASDAQ:NVDA$132.83 +1.03 (+0.78%) Closing price 04:00 PM EasternExtended Trading$132.86 +0.03 (+0.03%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.Recursion Pharmaceuticals NASDAQ:RXRX$4.14 +0.05 (+1.22%) Closing price 04:00 PM EasternExtended Trading$4.18 +0.04 (+1.09%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.WeRide NASDAQ:WRD$10.08 -0.18 (-1.75%) As of 04:00 PM EasternWeRide, Inc. engages in the development of an autonomous driving technology platform. It offers Robotaxi, Robobus, Robovan, Robosweeper, and advanced driving solutions, providing smart services in online ride-hailing, on-demand transport, urban logistics, and environmental sanitation. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
